# Dynavax Technologies Corporation clinical trials: 25 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials with Dynavax Technologies Corporation as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Dynavax Technologies Corporation: 25 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/dynavax-technologies-corporation

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 6, 2025 | NCT07207408 | Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age | Dynavax Technologies Corporation | Phase 2 | Active not recruiting | Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07207408) |
| August 26, 2024 | NCT06569823 | Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and... | Dynavax Technologies Corporation | Phase 1/2 | Active not recruiting | Shingles, Herpes Zoster, Vaccine-Preventable Diseases | 764 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06569823) |
| August 18, 2022 | NCT05506969 | Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55... | Dynavax Technologies Corporation | Phase 2 | Completed | Plague, Pneumonic, Plague, Vaccine-Preventable Diseases | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05506969) |
| February 18, 2022 | NCT05245838 | Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix®... | Dynavax Technologies Corporation | Phase 1 | Completed | Shingles, Herpes Zoster, Vaccine-Preventable Diseases | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05245838) |
| May 2, 2019 | NCT03934736 | HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis | Dynavax Technologies Corporation | Phase 1 | Completed | End Stage Renal Disease on Hemodialysis (Diagnosis) | 119 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03934736) |
| September 10, 2018 | NCT03664648 | DV2-HBV-27: Observational Pregnancy Registry | Dynavax Technologies Corporation | Observational | Unknown | Pregnant | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03664648) |
| October 31, 2017 | NCT03326752 | Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC | Dynavax Technologies Corporation | Phase 1 | Completed | Advanced Non Small Cell Lung Cancer | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03326752) |
| August 13, 2015 | NCT02521870 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or... | Dynavax Technologies Corporation | Phase 1/2 | Terminated | Metastatic Melanoma, Head Neck Cancer | 241 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02521870) |
| October 16, 2014 | NCT02266147 | Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma | Dynavax Technologies Corporation | Phase 1/2 | Terminated | B-cell Lymphoma | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02266147) |
| April 21, 2014 | NCT02117934 | Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine | Dynavax Technologies Corporation | Phase 3 | Completed | Healthy | 8,374 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02117934) |
| December 3, 2013 | NCT01999699 | A Study of the Immune Response to Heplisav in Healthy Older Adults | Dynavax Technologies Corporation | Phase 1 | Completed | Hepatitis B | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01999699) |
| January 25, 2011 | NCT01282762 | Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease | Dynavax Technologies Corporation | Observational | Completed | Chronic Kidney Disease | 147 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01282762) |
| September 6, 2010 | NCT01195246 | Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis | Dynavax Technologies Corporation | Phase 3 | Completed | End Stage Renal Disease | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01195246) |
| December 2, 2009 | NCT01023230 | A Study to Assess DV-601 in Subjects With Chronic Hepatitis B | Dynavax Technologies Corporation | Phase 1 | Completed | Hepatitis B, Chronic | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01023230) |
| November 2, 2009 | NCT01005407 | Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine | Dynavax Technologies Corporation | Phase 3 | Completed | Healthy | 2,452 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01005407) |
| September 28, 2009 | NCT00985426 | Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients | Dynavax Technologies Corporation | Phase 3 | Completed | Chronic Kidney Disease | 521 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00985426) |
| January 16, 2009 | NCT00823862 | Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection | Dynavax Technologies Corporation | Phase 1 | Completed | Chronic Hepatitis C | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00823862) |
| January 23, 2008 | NCT00599001 | Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males | Dynavax Technologies Corporation | Phase 1 | Completed | Healthy | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00599001) |
| October 1, 2007 | NCT00537355 | An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber | Dynavax Technologies Corporation | Phase 2 | Completed | Rhinitis, Allergic, Seasonal | 271 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00537355) |
| August 3, 2007 | NCT00511095 | Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine | Dynavax Technologies Corporation | Phase 2 | Completed | Hepatitis B | 207 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00511095) |
| July 9, 2007 | NCT00498212 | A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease | Dynavax Technologies Corporation | Phase 2 | Terminated | Hepatitis B | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00498212) |
| February 15, 2007 | NCT00435812 | Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine | Dynavax Technologies Corporation | Phase 3 | Completed | Hepatitis B | 2,428 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00435812) |
| January 25, 2007 | NCT00426712 | Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients | Dynavax Technologies Corporation | Phase 1 | Completed | Hepatitis B | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00426712) |
| November 23, 2006 | NCT00403052 | A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated... | Dynavax Technologies Corporation | Phase 1 | Terminated | Colorectal Neoplasms | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00403052) |
| October 13, 2006 | NCT00387738 | Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults | Dynavax Technologies Corporation | Phase 2 | Terminated | Rhinitis, Allergic, Seasonal | 738 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00387738) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 9 |
| Phase 1/2 | 3 |
| Phase 2 | 6 |
| Phase 3 | 5 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 17 |
| Terminated | 5 |
| Active not recruiting | 2 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hepatitis B | 13 |
| Hepatitis | 9 |
| Kidney Failure, Chronic | 5 |
| Renal Insufficiency, Chronic | 4 |
| Renal Insufficiency | 3 |
| Vaccine-Preventable Diseases | 3 |
| Rhinitis, Allergic, Seasonal | 2 |
| Hypersensitivity | 2 |
| Herpes Zoster | 2 |
| Neoplasms | 2 |
| Rhinitis | 1 |
| Kidney Diseases | 1 |
| Rhinitis, Allergic | 1 |
| Lymphoma, B-Cell | 1 |
| Hepatitis C, Chronic | 1 |
| Colorectal Neoplasms | 1 |
| Carcinoma | 1 |
| Neoplasm Metastasis | 1 |
| Melanoma | 1 |
| Head and Neck Neoplasms | 1 |
| Skin Neoplasms | 1 |
| Squamous Cell Carcinoma of Head and Neck | 1 |
| Lung Neoplasms | 1 |
| Hepatitis B, Chronic | 1 |
| Disease | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Montessori schools in the United States](https://specstream.ai/data/businesses/montessori-schools/united-states)
- [Pan Asian restaurants in the United States](https://specstream.ai/data/businesses/pan-asian-restaurants/united-states)
- [Pool cleaning companies in the United States](https://specstream.ai/data/businesses/pool-cleaning-companies/united-states)
- [Refinishing companies in the United States](https://specstream.ai/data/businesses/refinishing-companies/united-states)
- [Smoothie and juice bars in the United States](https://specstream.ai/data/businesses/smoothie-and-juice-bars/united-states)
- [Telecommunications services in the United States](https://specstream.ai/data/businesses/telecommunications-services/united-states)
